10 February 2017 - EU PAS Register increases transparency of research in medicines after they have been authorised in the EU
The 1,000th study has been uploaded in the European Union electronic Register of Post-Authorisation Studies (EU PAS).
The EU PAS Register provides a wealth of information on the safety and effectiveness of authorised medicines. It is an openly accessible platform with information on post authorisation research in medicines already marketed in Europe and includes study protocols, study results, related publications and other relevant information.
The information in the EU PAS Register reduces publication bias through increased transparency of medicines research, improves the quality of post-authorisation studies by facilitating peer-review of protocols and results, facilitates collaboration among stakeholders, and ensures compliance with EU pharmacovigilance legislation requirements.